![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
THSTI has entered into a research collaboration with Nanogen Pharmaceutical, which is developing a new vaccine for COVID-19 named Nano Covax which is the first Covid-19 vaccine to be approved by Vietnam’s Ministry of Health to conduct clinical trial in Vietnam.
Lead Product(s): Nanocovax
Therapeutic Area: Infections and Infectious Diseases Product Name: Nanocovax
Highest Development Status: Phase IIIProduct Type: Vaccine
Recipient: The Translational Health Science and Technology Institute
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 27, 2021